



Jean Dudler

Contact

Jean Dudler

Publications (9)

Riek M, Scherer A, Möller B, Ciurea A, Von Mühlengen I, Gabay C, Kyburz D, Brulhart L, von Kempis J, Mueller R, Hasler P, Strahm T, von Känel S, Zufferey P, Dudler J, Finckh A. Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care. *Sci Rep* 2023; 13:17776.

Amstad A, Papagiannoulis E, Scherer A, Rubbert-Roth A, Finckh A, Mueller R, Dudler J, Möller B, Villiger P, Schulz M, Kyburz D. Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy. *Rheumatology (Oxford)* 2022; 62:89-97.

Alpizar-Rodriguez D, Gabay C, Courvoisier D, Lamacchia C, Mahler M, Roux-Lombard P, Von Mühlengen I, Walker U, Kyburz D, Zufferey P, Ciurea A, Dudler J, Möller B, Müller R, Finckh A. Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis. *Rheumatology (Oxford)* 2017; 56:1579-1585.

Alpizar-Rodriguez D, Bas S, Gascon D, Lamacchia C, Roux-Lombard P, Lauper K, Nissen M, Courvoisier D, Gabay C, Mahler M, Zufferey P, Brulhart L, Müller R, Möller B, Dudler J, Ciurea A, Walker U, Von Mühlengen I, Kyburz D, Finckh A. The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis. *Clin Rheumatol* 2017

Müller R, Gengenbacher M, Richter S, Dudler J, Möller B, von Kempis J. Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK). *Arthritis Res Ther* 2016; 18:88.

Boehncke W, Yawalkar N, Villiger P, Navarini A, Möller B, Michel B, Laffitte E, Kyburz D, Häusermann P, Hasler P, Hasler F, Dudler J, Conrad C, Anliker M, Gabay C. The dermatologists' role in managing psoriatic arthritis: results of a Swiss Delphi exercise intended to improve collaboration with rheumatologists. *Dermatology (Basel)* 2015; 230:75-81.

Ciurea A, Weber U, Boonen A, Dougados M, van der Heijde D, Michel B, Nissen M, Müller R, Weiss B, Tamborrini G, Rufibach K, Stekhoven D, Kissling R, Beyeler B, Dudler J, Bernhard J, Exer P, Scherer A. Rheumatologists of the Swiss Clinical Quality Management Program for Axial Spondyloarthritis. Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort. *Arthritis Rheum* 2013; 65:3096-106.

von Kempis J, Dudler J, Hasler P, Kyburz D, Tyndall A, Zufferey P, Villiger P. Use of abatacept in rheumatoid arthritis. *Swiss Med Wkly* 2012; 142:w13581.

Walker U, Courvoisier D, Dudler J, Aeberli D, von Kempis J, Scherer A, Finckh A. Swiss Clinical Quality Management Programme in Rheumatic Diseases. Do new biologics meet the unmet medical need in rheumatoid arthritis? Safety and efficacy of abatacept following B-cell depletion. *Rheumatology (Oxford)* 2010; 50:243-4.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch